Intellia Therapeutics, Inc.(NTLA)
Biotechnology
Gene Therapy & Gene Editing
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | BASTA JAMES EVP, General Counsel | Sale | -1,211 | -0.77%156,794 | $13.78 | $16,688 | View SEC filing | |
| 2026-03-03 | Clark Eliana EVP, Chief Technical Officer | Sale | -607 | -0.64%93,864 | $13.78 | $8,364 | View SEC filing | |
| 2026-01-07 | LEONARD JOHN M President and CEO | Sale | -34,146 | -3.26%1,013,339 | $9.21 | $314,485 | View SEC filing | |
| 2026-01-07 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | -8,508 | -7.95%98,533 | $9.21 | $78,359 | View SEC filing | |
| 2026-01-07 | BASTA JAMES EVP, General Counsel | Sale | -10,397 | -9.29%101,528 | $9.21 | $95,756 | View SEC filing | |
| 2026-01-07 | Cohen Fred E Director | Purchase | +150,000 | +261.08%207,453 | $9.35 | $1,402,500 | View SEC filing | |
| 2026-01-07 | Lebwohl David EVP, Chief Medical Officer | Sale | -11,903 | -8.94%121,249 | $9.21 | $109,627 | View SEC filing | |
| 2026-01-07 | Clark Eliana EVP, Chief Technical Officer | Sale | -9,515 | -9.85%87,118 | $9.21 | $87,633 | View SEC filing | |
| 2026-01-07 | Dulac Edward J III EVP, Chief Financial Officer | Sale | -6,379 | -6.01%99,683 | $9.21 | $58,751 | View SEC filing | |
| 2026-01-07 | Dube Michael P VP, Chief Accounting Officer | Sale | -2,989 | -5.41%52,277 | $9.21 | $27,529 | View SEC filing | |
| 2025-12-12 | LEONARD JOHN M President and CEO | Sale | -88,146 | -7.82%1,038,928 | $9.49 | $836,384 | View SEC filing | |
| 2025-10-03 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | -31 | -0.03%105,184 | $17.38 | $539 | View SEC filing | |
| 2025-10-03 | Dube Michael P VP, Chief Accounting Officer | Sale | -1,871 | -3.27%55,266 | $17.38 | $32,518 | View SEC filing | |
| 2025-08-22 | CHASE WILLIAM J Director | Purchase | +100,000 | +288.24%134,693 | $10.03 | $1,003,000 | View SEC filing | |
| 2025-07-25 | Dulac Edward J III EVP, Chief Financial Officer | Sale | -7,462 | -6.57%106,062 | $14.02 | $104,617 | View SEC filing | |
| 2025-07-03 | Clark Eliana EVP, Chief Technical Officer | Sale | -1,022 | -1.06%95,369 | $9.82 | $10,036 | View SEC filing | |
| 2025-07-03 | Dube Michael P VP, Chief Accounting Officer | Sale | -2,503 | -4.20%57,137 | $9.95 | $24,905 | View SEC filing | |
| 2025-07-02 | GOODMAN JESSE Director | Sale | -3,094 | -11.27%24,359 | $9.39 | $29,068 | View SEC filing | |
| 2025-05-01 | Bhanji Muna Director | Sale | -265 | -1.36%19,203 | $8.50 | $2,253 | View SEC filing | |
| 2025-03-04 | Clark Eliana EVP, Chief Technical Officer | Sale | -679 | -0.71%95,369 | $8.99 | $6,104 | View SEC filing | |
| 2025-03-04 | BASTA JAMES EVP, General Counsel | Sale | -2,572 | -2.25%111,925 | $8.99 | $23,122 | View SEC filing | |
| 2025-01-31 | Bhanji Muna Director | Sale | -265 | -1.34%19,468 | $9.97 | $2,642 | View SEC filing | |
| 2025-01-07 | Dube Michael P VP, Chief Accounting Officer | Sale | -1,372 | -2.92%45,640 | $12.18 | $16,711 | View SEC filing | |
| 2025-01-07 | BASTA JAMES EVP, General Counsel | Sale | -7,074 | -8.67%74,497 | $12.18 | $86,161 | View SEC filing | |
| 2025-01-07 | Lebwohl David EVP, Chief Medical Officer | Sale | -9,557 | -9.83%87,666 | $12.18 | $116,404 | View SEC filing |
1-25 of 128